Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1139 participants.
Also called NCT01335997
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,139 participants
- Sponsor
- Registry
-
NCT01335997 -
2011-001007-12
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01335997. Randomized; double masking; primary purpose treatment. Start 2011-05-01 (actual); primary completion 2012-01-01 (actual). Results posted on 2016-06-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
- Condition
- Primary Hypercholesterolemia
- Condition
- Mixed Dyslipidemia
- Intervention (Drug)
- ER niacin/laropiprant (ERN/LRPT)
- Intervention (Drug)
- ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
- Intervention (Drug)
- Simvastatin (SIM)
- Intervention (Drug)
- Placebo Run-In
- Intervention (Drug)
- SIM-matching placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01335997- Content hash
7a7d50a6ecf56ab5e2eb1ec08c6f2266f445b19c47aaed3c02cdd92ab4cb66d4